Literature DB >> 34888629

Somatic mutations in rheumatological diseases: VEXAS syndrome and beyond.

Keith A Sikora1, Kristina V Wells1, Ertugrul Cagri Bolek1,2, Adrianna I Jones1, Peter C Grayson1.   

Abstract

Discovery of the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome demonstrates that somatic mutations in haematological precursor cells can cause adult-onset, complex inflammatory disease. Unlike germline mutations, somatic mutations occur throughout the lifespan, are restricted to specific tissue types, and may play a causal role in non-heritable rheumatological diseases, especially conditions that start in later life. Improvements in sequencing technology have enabled researchers and clinicians to detect somatic mutations in various tissue types, especially blood. Understanding the relationships between cell-specific acquired mutations and inflammation is likely to yield key insights into causal factors that underlie many rheumatological diseases. The objective of this review is to detail how somatic mutations are likely to be relevant to clinicians who care for patients with rheumatological diseases, with particular focus on the pathogenetic mechanisms of the VEXAS syndrome. Published by Oxford University Press on behalf of the British Society for Rheumatology 2021. This work is written by a US Government employee and is in the public domain in the US.

Entities:  

Keywords:  VEXAS syndrome; autoimmune disease; autoinflammatory disease; clonal haematopoiesis; somatic mutations

Mesh:

Year:  2022        PMID: 34888629      PMCID: PMC9348615          DOI: 10.1093/rheumatology/keab868

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.046


  115 in total

Review 1.  Perilous journey: a tour of the ubiquitin-proteasome system.

Authors:  Gary Kleiger; Thibault Mayor
Journal:  Trends Cell Biol       Date:  2014-01-20       Impact factor: 20.808

Review 2.  Somatic hypermutation.

Authors:  M S Neuberger; C Milstein
Journal:  Curr Opin Immunol       Date:  1995-04       Impact factor: 7.486

3.  Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.

Authors:  Paul M Ridker; Jean G MacFadyen; Brendan M Everett; Peter Libby; Tom Thuren; Robert J Glynn
Journal:  Lancet       Date:  2017-11-13       Impact factor: 79.321

4.  The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis.

Authors:  S E Straus; E S Jaffe; J M Puck; J K Dale; K B Elkon; A Rösen-Wolff; A M Peters; M C Sneller; C W Hallahan; J Wang; R E Fischer; C E Jackson; A Y Lin; C Bäumler; E Siegert; A Marx; A K Vaishnaw; T Grodzicky; T A Fleisher; M J Lenardo
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

5.  Somatic Mosaic NLRP3 Mutations and Inflammasome Activation in Late-Onset Chronic Urticaria.

Authors:  Eman Assrawi; Camille Louvrier; Clémence Lepelletier; Sophie Georgin-Lavialle; Jean-David Bouaziz; Fawaz Awad; Florence Moinet; Philippe Moguelet; Marie Dominique Vignon-Pennamen; William Piterboth; Claire Jumeau; Laetitia Cobret; Elma El Khouri; Bruno Copin; Philippe Duquesnoy; Marie Legendre; Gilles Grateau; Sonia A Karabina; Serge Amselem; Irina Giurgea
Journal:  J Invest Dermatol       Date:  2019-09-09       Impact factor: 8.551

6.  Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency.

Authors:  Hyung J Chun; Lixin Zheng; Manzoor Ahmad; Jin Wang; Christina K Speirs; Richard M Siegel; Janet K Dale; Jennifer Puck; Joie Davis; Craig G Hall; Suzanne Skoda-Smith; T Prescott Atkinson; Stephen E Straus; Michael J Lenardo
Journal:  Nature       Date:  2002-09-26       Impact factor: 49.962

7.  Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes.

Authors:  R H Jacobs; M A Cornbleet; J W Vardiman; R A Larson; M M Le Beau; J D Rowley
Journal:  Blood       Date:  1986-06       Impact factor: 22.113

8.  Human ubiquitin-activating enzyme, E1. Indication of potential nuclear and cytoplasmic subpopulations using epitope-tagged cDNA constructs.

Authors:  P M Handley-Gearhart; A G Stephen; J S Trausch-Azar; A Ciechanover; A L Schwartz
Journal:  J Biol Chem       Date:  1994-12-30       Impact factor: 5.157

Review 9.  VEXAS syndrome.

Authors:  Peter C Grayson; Bhavisha A Patel; Neal S Young
Journal:  Blood       Date:  2021-07-01       Impact factor: 25.476

10.  Complex Autoinflammatory Syndrome Unveils Fundamental Principles of JAK1 Kinase Transcriptional and Biochemical Function.

Authors:  Conor N Gruber; Jorg J A Calis; Sofija Buta; Gilad Evrony; Jerome C Martin; Skyler A Uhl; Rachel Caron; Lauren Jarchin; David Dunkin; Robert Phelps; Bryn D Webb; Jeffrey M Saland; Miriam Merad; Jordan S Orange; Emily M Mace; Brad R Rosenberg; Bruce D Gelb; Dusan Bogunovic
Journal:  Immunity       Date:  2020-08-03       Impact factor: 31.745

View more
  2 in total

1.  Trisomy 8 Associated Clonal Cytopenia Featured With Acquired Auto-Inflammation and Its Response to JAK Inhibitors.

Authors:  Yakai Fu; Wanlong Wu; Zhiwei Chen; Liyang Gu; Xiaodong Wang; Shuang Ye
Journal:  Front Med (Lausanne)       Date:  2022-04-25

Review 2.  [VEXAS syndrome].

Authors:  M Zeeck; I Kötter; M Krusche
Journal:  Z Rheumatol       Date:  2022-02-18       Impact factor: 1.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.